Please ensure Javascript is enabled for purposes of website accessibility

Why iTeos Therapeutics Stock Soared Today

By Joe Tenebruso - Jun 14, 2021 at 4:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech struck a potential $2 billion deal with a pharmaceutical giant.

What happened

Shares of iTeos Therapeutics (ITOS 0.74%) surged 37% on Monday after it reached an agreement with GlaxoSmithKline (GSK -0.07%) to co-develop an experimental cancer treatment known as EOS-448. 

So what

EOS-448 is a monoclonal antibody treatment for patients with cancer. It's currently being evaluated in a phase 1 study in patients with advanced solid tumors. GlaxoSmithKline also intends to begin new combination studies of EOS-448 with some of its other immuno-oncology therapies next year.

Two people are shaking hands.

iTeos Therapeutics and GlaxoSmithKline struck a major new development deal. Image source: Getty Images.

The deal could be worth more than $2 billion to iTeos. Under the terms of the agreement, the biotech would receive an upfront payment of $625 million. It could also receive milestone payments of as much as $1.45 billion, if certain conditions are met. Better still, GlaxoSmithKline and iTeos will equally share EOS-448's potential profits in the U.S., and iTeos will receive royalty payments for sales in international markets.

Now what

The partnership with GlaxoSmithKline will bolster iTeos' research and distribution capabilities, as well as its cash reserves. "This collaboration allows us to accelerate and expand the clinical development of EOS-448," iTeos CEO Michel Detheux said in a press release. "We are more confident than ever in our ability to succeed."

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends GlaxoSmithKline. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

iTeos Therapeutics, Inc. Stock Quote
iTeos Therapeutics, Inc.
ITOS
$27.25 (0.74%) $0.20
GSK Stock Quote
GSK
GSK
$40.57 (-0.07%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.